Proteomics, Metabolomics, And Protein Interactomics In The Characterization Of The Molecular Features Of Major Depressive Disorder

Omics technologies emerged as complementary strategies to genomics in the attempt to understand human illnesses. In general, proteomics technologies emerged earlier than those of metabolomics for major depressive disorder (MDD) research, but both are driven by the identification of proteins and/or metabolites that can delineate a comprehensive characterization of MDD's molecular mechanisms, as well as lead to the identification of biomarker candidates of all types-prognosis, diagnosis, treatment, and patient stratification. Also, one can explore protein and metabolite interactomes in order to pinpoint additional molecules associated with the disease that had not been picked up initially. Here, results and methodological aspects of MDD research using proteomics, metabolomics, and protein interactomics are reviewed, focusing on human samples. © 2014, AICH-Servier Research Group.1616373Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level (2014), http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf, World Health Organization. Available at Updated December 1, 2011. Accessed January 7Murrough, J.W., Charney, D.S., Is there anything really novel on the anti-depressant horizon (2012) Curr Psychiatry Rep., 14, pp. 643-649DiMatteo, M.R., Lepper, H.S., Croghan, T.W., Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence (2000) Arch Intern Med., 160, pp. 2101-2107Martins-de-Souza, D., Comprehending depression through proteomics (2012) Int J Neuropsychopharmacol., 15, pp. 1373-1374Wilkins, M.R., Pasquali, C., Appel, R.D., From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis (1996) Biotechnology (N Y)., 14, pp. 61-65O'Farrell, P.H., High resolution two-dimensional electrophoresis of proteins (1975) J Biol Chem., 250, pp. 4007-4021Bjellqvist, B., Ek, K., Righetti, P.G., Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications (1982) J Biochem Biophys Methods., 6, pp. 317-339Gorg, A., Postel, W., Gunther, S., Approach to stationary two-dimensional pattern: influence of focusing time and immobiline/carrier ampholytes concentrations (1988) Electrophoresis., 9, pp. 37-46. , of the LMU, and Prof Wagner Gattaz from the Institute of Psychiatry of the University of Sao Paulo. The author is funded by FAPESP (Sao Paulo Research Foundation, grant 2013/08711-3)Hubner, N.C., Ren, S., Mann, M., Peptide separation with immobilized pI strips is an attractive alternative to in-gel protein digestion for proteome analysis (2008) Proteomics., 8, pp. 4862-4872Westermeier, R., Postel, W., Weser, J., Gorg, A., High-resolution two-dimen-sional electrophoresis with isoelectric focusing in immobilized pH gradients (1983) J Biochem Biophys Methods., 8, pp. 321-330Unlu, M., Morgan, M.E., Minden, J.S., Difference gel electrophoresis: a single gel method for detecting changes in protein extracts (1997) Electrophoresis., 18, pp. 2071-2077Link, A.J., Eng, J., Schieltz, D.M., Direct analysis of protein complexes using mass spectrometry (1999) Nat Biotechnol., 17, pp. 676-682Filiou, M.D., Martins-de-Souza, D., Guest, P.C., Bahn, S., Turck, C.W., To label or not to label: applications of quantitative proteomics in neuroscience research (2012) Proteomics., 12, pp. 736-747Gygi, S.P., Rist, B., Gerber, S.A., Turecek, F., Gelb, M.H., Aebersold, R., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags (1999) Nat Biotechnol., 17, pp. 994-999Ross, P.L., Huang, Y.N., Marchese, J.N., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents (2004) Mol Cell Proteomics., 3, pp. 1154-1169Ong, S.E., Blagoev, B., Kratchmarova, I., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics (2002) Mol Cell Proteomics., 1, pp. 376-386Martins-de-Souza, D., Guest, P.C., Vanattou-Saifoudine, N., Harris, L.W., Bahn, S., Proteomic technologies for biomarker studies in psychiatry: advances and needs (2011) Int Rev Neurobiol., 101, pp. 65-94Martins-de-Souza, D., Guest, P.C., Rahmoune, H., Bahn, S., Proteomic approaches to unravel the complexity of schizophrenia (2012) Exp Rev Proteomics., 9, pp. 97-108Oliveira, B.M., Martins-de-Souza, D., Large-scale analyses of schizophrenia proteome (2013) Rev Psiq Clín., 40, pp. 16-19Martins-de-Souza, D., Guest, P.C., Harris, L.W., Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients (2012) Transl Psychiatry., 2, pp. e87Kaidanovich-Beilin, O., Cha, D.S., McIntyre, R.S., Crosstalk between metabolic and neuropsychiatric disorders (2012) F1000 Biol Rep., 4, p. 14Rezin, G.T., Amboni, G., Zugno, A.I., Quevedo, J., Streck, E.L., Mitochondrial dysfunction and psychiatric disorders (2009) Neurochem Res., 34, pp. 1021-1029Stanley, J.A., In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders (2002) Can J Psychiatry., 47, pp. 315-326Martins-de-Souza, D., Harris, L.W., Guest, P.C., Bahn, S., The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics (2011) Antioxid Redox Signal., 15, pp. 2067-2079Filiou, M.D., Zhang, Y., Teplytska, L., Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways (2011) Biol Psychiatry., 70, pp. 1074-1082Varadarajulu, J., Schmitt, A., Falkai, P., Alsaif, M., Turck, C.W., Martins-de-Souza, D., Differential expression of HINT1 in schizophrenia brain tissue (2012) Eur Arch Psychiatry Clin Neurosci., 262, pp. 167-172Barbier, E., Wang, J.B., Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level (2009) BMC Neurosci., 10, p. 132Varadarajulu, J., Lebar, M., Krishnamoorthy, G., Increased anxiety-related behaviour in HINT1 knockout mice (2011) BehavBrain Res., 220, pp. 305-311Martins-de-Souza, D., Guest, P.C., Vanattou-Saifoudine, N., Rahmoune, H., Bahn, S., Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function (2012) Eur Arch Psychiatry Clin Neurosci., 262, pp. 657-666Johnston-Wilson, N.L., Sims, C.D., Hofmann, J.P., Disease-specific alter-ations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder (2000) The Stanley Neuropathology Consortium. Mol Psychiatry., 5, pp. 142-149Beasley, C.L., Pennington, K., Behan, A., Wait, R., Dunn, M.J., Cotter, D., Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evi-dence for disease-associated changes (2006) Proteomics., 6, pp. 3414-3425Hensley, K., Venkova, K., Christov, A., Gunning, W., Park, J., Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications (2011) Mol Neurobiol., 43, pp. 180-191Huang, J.T., Leweke, F.M., Oxley, D., Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis (2006) PLoS Med., 3, pp. e428Ditzen, C., Tang, N., Jastorff, A.M., Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology (2012) Neuropsychopharmacology., 37, pp. 1013-1025Martins-De-Souza, D., Wobrock, T., Zerr, I., Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls (2010) World J Biol Psychiatry., 11, pp. 719-728Carboni, L., Becchi, S., Piubelli, C., Early-life stress and antidepressants modulate peripheral biomarkers in a gene-environment rat model of depression (2010) Prog Neuropsychopharmacol Biol Psychiatry., 34, pp. 1037-1048Zhang, Y., Filiou, M.D., Reckow, S., Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways (2011) Mol Cell Proteomics., 10, pp. M111008110Xu, H.B., Zhang, R.F., Luo, D., Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation (2012) Int J Neuropsychopharmacol., 15, pp. 1413-1425Martins-de-Souza, D., Is the word 'biomarker' being properly used by proteomics research in neuroscience? (2010) Eur Arch Psychiatry Clin Neurosci, 260, pp. 561-562Martins-de-Souza, D., Maccarrone, G., Ising, M., Blood mononuclear cell proteome suggests Integrin and Ras signaling as critical pathways for antidepressant treatment response (2014) Biol Psychiatry., , In pressRaamsdonk, L.M., Teusink, B., Broadhurst, D., A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations (2001) Nat Biotechnol., 19, pp. 45-50Nicholson, J.K., Lindon, J.C., Holmes, E., 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via mul-tivariate statistical analysis of biological NMR spectroscopic data (1999) Xenobiotica., 29, pp. 1181-1189Kaddurah-Daouk, R., Krishnan, K.R., Metabolomics: a global biochemical approach to the study of central nervous system diseases (2009) Neuropsychopharmacology., 34, pp. 173-186Shin, M.H., Lee do, Y., Liu, K.H., Fiehn, O., Kim, K.H., Evaluation of sampling and extraction methodologies for the global metabolic profiling of Saccharophagus degradans (2010) Anal Chem., 82, pp. 6660-6666Cubbon, S., Antonio, C., Wilson, J., Thomas-Oates, J., Metabolomic applications of HILIC-LC-MS (2010) Mass Spectrom Rev., 29, pp. 671-684Rojo, D., Barbas, C., Ruperez, F.J., LC-MS metabolomics of polar compounds (2012) Bioanalysis., 4, pp. 1235-1243Nemutlu, E., Zhang, S., Juranic, N.O., Terzic, A., Macura, S., Dzeja, P., 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases (2012) Croat Med J., 53, pp. 529-534Smolinska, A., Blanchet, L., Buydens, L.M., Wijmenga, S.S., NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review (2012) Anal Chim Acta., 750, pp. 82-97Reo, N.V., NMR-based metabolomics (2002) Drug Chem Toxicol., 25, pp. 375-382Harada, K., Fukusaki, E., Bamba, T., Sato, F., Kobayashi, A., In vivo 15N-enrich-ment of metabolites in suspension cultured cells and its application to metabolomics (2006) Biotechnol Prog., 22, pp. 1003-1011Zamboni, N., Sauer, U., Novel biological insights through metabolomics and 13C-flux analysis (2009) Curr Opin Microbiol., 12, pp. 553-558Becker, S., Kortz, L., Helmschrodt, C., Thiery, J., Ceglarek, U., LC-MS-based metabolomics in the clinical laboratory (2012) J Chromatogr B Analyt Technol Biomed Life Sci., 883-884, pp. 68-75Dettmer, K., Aronov, P.A., Hammock, B.D., Mass spectrometry-based metabolomics (2007) Mass Spectrom Rev., 26, pp. 51-78Milne, S.B., Mathews, T.P., Myers, D.S., Ivanova, P.T., Brown, H.A., Sum of the parts: mass spectrometry-based metabolomics (2013) Biochemistry., 52, pp. 3829-3840Garcia, A., Barbas, C., Gas chromatography-mass spectrometry (GC-MS)-based metabolomics (2011) Methods Mol Biol., 708, pp. 191-204Zhou, B., Xiao, J.F., Tuli, L., Ressom, H.W., LC-MS-based metabolomics (2012) Mol Biosyst., 8, pp. 470-481Ramautar, R., Somsen, G.W., de Jong, G.J., CE-MS for metabolomics: devel-opments and applications in the period 2010-2012 (2013) Electrophoresis., 34, pp. 86-98Lei, Z., Huhman, D.V., Sumner, L.W., Mass spectrometry strategies in metabolomics (2011) J Biol Chem., 286, pp. 25435-25442Dai, Y., Li, Z., Xue, L., Metabolomics study on the anti-depression effect of xiaoyaosan on rat model of chronic unpredictable mild stress (2010) J Ethnopharmacol., 128, pp. 482-489Zheng, S., Yu, M., Lu, X., Urinary metabonomic study on biochemical changes in chronic unpredictable mild stress model of depression (2010) Clin Chim Acta., 411, pp. 204-209Zhang, F., Jia, Z., Gao, P., Metabonomics study of urine and plasma in depression and excess fatigue rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry (2010) Mol Biosyst., 6, pp. 852-861Wang, X., Zeng, C., Lin, J., Metabonomics approach to assessing the modulatory effects of St John's wort, ginsenosides, and clomipramine in experimental depression (2012) J Proteome Res., 11, pp. 6223-6230Kaddurah-Daouk, R., Yuan, P., Boyle, S.H., Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile (2012) Sci Rep., 2, p. 667Paige, L.A., Mitchell, M.W., Krishnan, K.R., Kaddurah-Daouk, R., Steffens, D.C., A preliminary metabolomic analysis of older adults with and without depression (2007) Int J Geriatr Psychiatry., 22, pp. 418-423Steffens, D.C., Wei, J., Krishnan, K.R., Metabolomic differences in heart failure patients with and without major depression (2010) J Geriatr Psychiatry Neurol., 23, pp. 138-146Zheng, P., Gao, H.C., Li, Q., Plasma metabonomics as a novel diagnostic approach for major depressive disorder (2012) J Proteome Res., 11, pp. 1741-1748Zheng, P., Wang, Y., Chen, L., Identification and validation of urinary metabolite biomarkers for major depressive disorder (2013) Mol Cell Proteomics., 12, pp. 207-214Kaddurah-Daouk, R., Boyle, S.H., Matson, W., Pretreatment metabo-type as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept (2011) TranslPsychiatry., 1, pp. e26Kaddurah-Daouk, R., Bogdanov, M.B., Wikoff, W.R., Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo (2013) Transl Psychiatry., 3, pp. e223Martins-de-Souza, D., Translational strategies to schizophrenia from a proteomic perspective (2012) Transl Neurosci., 3, pp. 300-302Coulombe, B., Mapping the disease protein interactome: toward a molecular medicine GPS to accelerate drug and biomarker discovery (2011) J Proteome Res., 10, pp. 120-125Williamson, M.P., Sutcliffe, M.J., Protein-protein interactions (2010) Biochem Soc Trans., 38, pp. 875-878Chen, J., Zhou, J., Sanders, C.K., Nolan, J.P., Cai, H., A surface display yeast two-hybrid screening system for high-throughput protein interactome mapping (2009) Anal Biochem., 390, pp. 29-37Scifo, E., Szwajda, A., Debski, J., Drafting the CLN3 protein interac-tome in SH-SY5Y human neuroblastoma cells: a label-free quantitative pro-teomics approach (2013) J Proteome Res., 12, pp. 2101-2115Van Leene, J., Stals, H., Eeckhout, D., A tandem affinity purification-based technology platform to study the cell cycle interactome in Arabidopsis thaliana (2007) Mol Cell Proteomics., 6, pp. 1226-1238Markham, K., Bai, Y., Schmitt-Ulms, G., Co-immunoprecipitations revisited: an update on experimental concepts and their implementation for sensitive interactome investigations of endogenous proteins (2007) Anal Bioanal Chem., 389, pp. 461-473Bonfiglio, J.J., Maccarrone, G., Rewerts, C., Characterization of the B-Raf interactome in mouse hippocampal neuronal cells (2011) J Proteomics., 74, pp. 186-198Nikolsky, Y., Nikolskaya, T., Bugrim, A., Biological networks and analysis of experimental data in drug discovery (2005) Drug Discov Today., 10, pp. 653-662Stein, A., Mosca, R., Aloy, P., Three-dimensional modeling of protein inter-actions and complexes is going 'omics (2011) Curr Opin Struct Biol., 21, pp. 200-208Valencia, A., Pazos, F., Computational methods for the prediction of protein interactions (2002) Curr Opin Struct Biol., 12, pp. 368-373Weichhart, T., Saemann, M.D., The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications (2008) Ann Rheum Dis., 67 (SUPPL. 3), pp. 370-374Pilot-Storck, F., Chopin, E., Rual, J.F., Interactome mapping of the phos-phatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor (2010) Mol Cell Proteomics., 9, pp. 1578-1593Jia, P., Kao, C.F., Kuo, P.H., Zhao, Z., A comprehensive network and pathway analysis of candidate genes in major depressive disorder (2011) BMC Syst Biol., 5 (SUPPL. 3), pp. S12Sperner-Unterweger, B., Kohl, C., Fuchs, D., Immune changes and neuro-transmitters: Possible interactions in depression? (2014) Prog Neuropsychopharmacol Biol Psychiatry, 48, pp. 268-276Martins-de-Souza, D., Proteomics is not only a biomarker discovery tool (2009) Proteomics Clin Appl., 3, pp. 1136-1139Franceschini, A., Szklarczyk, D., Frankild, S., STRING v9.1: protein-pro-tein interaction networks, with increased coverage and integration. (2013) Nucleic Acids Res., 41 (DATABASE ISSUE), pp. D808-815Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L., Ideker, T., Cytoscape 2.8: new features for data integration and network visualization. (2011) Bioinformatics., 27, pp. 431-432Schrattenholz, A., Groebe, K., Soskic, V., Systems biology approaches and tools for analysis of interactomes and multi-target drugs (2010) Methods Mol Biol., 662, pp. 29-58Turck, C.W., Iris, F., Proteome-based pathway modelling of psychiatric dis-orders (2011) Pharmacopsychiatry., 44 (SUPPL. 1), pp. S54-61Filiou, M.D., Turck, C.W., Martins-de-Souza, D., Quantitative proteomics for investigating psychiatric disorders (2011) Proteomics Clin Appl., 5, pp. 38-49Gormanns, P., Mueller, N.S., Ditzen, C., Wolf, S., Holsboer, F., Turck, C.W., Phenome-transcriptome correlation unravels anxiety and depression related pathways (2011) J Psychiatr Res., 45, pp. 973-979Yang, Y., Yang, D., Tang, G., Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression (2013) Neuroscience., 247, pp. 191-200Bisgaard, C.F., Bak, S., Christensen, T., Jensen, O.N., Enghild, J.J., Wiborg, O., Vesicular signalling and immune modulation as hedonic fingerprints: pro-teomic profiling in the chronic mild stress depression model (2012) J Psychopharmacol., 26, pp. 1569-1583Xu, Z., Hou, B., Zhang, Y., Antidepressive behaviors induced byenriched environment might be modulated by glucocorticoid levels (2009) Eur Neuropsychopharmacol., 19, pp. 868-875Carboni, L., Peripheral biomarkers in animal models of major depressive disorder (2013) Dis Markers., 35, p. 8Connolly, K.R., Thase, M.E., Emerging drugs for major depressive disorder (2012) Expert Opin Emerg Drugs., 17, pp. 105-126Martins-de-Souza, D., Biomarkers for psychiatric disorders: where are we standing? (2013) Dis Markers, 35, pp. 1-2Domenici, E., Wille, D.R., Tozzi, F., Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control col-lections (2010) PLoS One., 5, pp. e9166Raedler, T.J., Wiedemann, K., CSF-studies in neuropsychiatric disorders (2006) Neuro Endocrinol Lett., 27, pp. 297-305Bahn, S., Schwarz, E., Harris, L.W., Martins-de-Souza, D., Rahmoune, H., Guest, P.C., Biomarker blood tests for diagnosis and management of mental disorders: focus on schizophrenia (2013) Rev Psiq Clín., 40, p.